November 24, 2016 - By Ruchi Gupta · 0 Comments
Johnson & Johnson (NYSE:JNJ) institutional sentiment decreased to 0.82 in Q2 2016. Its down -0.04, from 0.86 in 2016Q1. The ratio dived, as 806 investment professionals increased and started new holdings, while 939 trimmed and sold equity positions in Johnson & Johnson. The investment professionals in our partner’s database reported: 1.75 billion shares, down from 1.84 billion shares in 2016Q1. Also, the number of investment professionals holding Johnson & Johnson in their top 10 holdings increased from 665 to 730 for an increase of 65. Sold All: 49 Reduced: 890 Increased: 703 New Position: 103.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has a market cap of $301.57 billion. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. It has a 19.82 P/E ratio. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
The stock increased 0.29% or $0.33 on November 23, hitting $113.07. About 8.47M shares traded hands or 8.04% up from the average. Johnson & Johnson (NYSE:JNJ) has declined 0.22% since April 22, 2016 and is downtrending. It has underperformed by 5.63% the S&P500.
Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 24 before the open. They expect $1.56 EPS, up 8.33% or $0.12 from last year’s $1.44 per share. JNJ’s profit will be $4.16 billion for 18.12 P/E if the $1.56 EPS becomes a reality. After $1.68 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
According to Zacks Investment Research, “Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.”
Robert Wood Johnson Foundation holds 99.9% of its portfolio in Johnson & Johnson for 13.00 million shares. Trb Advisors Lp owns 15,000 shares or 18.67% of their US portfolio. Moreover, Pettee Investors Inc. has 17.25% invested in the company for 146,992 shares. The Ohio-based Cincinnati Indemnity Co has invested 13.12% in the stock. March Altus Capital Management Lp, a Connecticut-based fund reported 13,000 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 buying transaction, and 4 insider sales for $6.89 million net activity.
Ratings analysis reveals 54% of Johnson & Johnson’s analysts are positive. Out of 13 Wall Street analysts rating Johnson & Johnson, 7 give it “Buy”, 1 “Sell” rating, while 5 recommend “Hold”. The lowest target is $90 while the high is $145. The stock’s average target of $116.69 is 3.20% above today’s ($113.07) share price. JNJ was included in 38 notes of analysts from August 7, 2015. Cowen & Co maintained it with “Outperform” rating and $114 target price in Tuesday, August 25 report. The stock of Johnson & Johnson (NYSE:JNJ) has “Outperform” rating given on Wednesday, October 7 by RBC Capital Markets. Piper Jaffray reinitiated it with “Neutral” rating and $105.0 target price in Monday, October 5 report. The firm has “Hold” rating by Jefferies given on Tuesday, June 14. The company was maintained on Wednesday, April 20 by Argus Research. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by UBS on Wednesday, October 19. The firm has “Neutral” rating by Atlantic Securities given on Friday, December 18. The stock has “Overweight” rating given by Barclays Capital on Wednesday, April 20. UBS initiated the shares of JNJ in a report on Tuesday, September 22 with “Buy” rating. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”.
Johnson & Johnson, incorporated on November 10, 1887, is a holding company. The Firm and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. The Company’s primary focus is on products related to human health and well-being. The Company’s subsidiaries operate over 120 manufacturing facilities. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom. The Firm has over 250 operating companies, which conduct business around the world.
More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “3 Irrefutable Reasons to Sell Johnson & Johnson Stock” on November 21, 2016, also Thestreet.com with their article: “Johnson & Johnson Stock Goes Into Full Breakdown” published on November 22, 2016, Realmoney.Thestreet.com published: “No More Tears: How to Play a Likely Johnson & Johnson Rally” on November 23, 2016. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Fool.com and their article: “Johnson & Johnson Takes Aim at AbbVie” published on November 18, 2016 as well as Fool.com‘s news article titled: “Better Buy: Johnson & Johnson vs. Merck” with publication date: November 15, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta